Sample Prep:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
Sequencing:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
In Vitro:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
Drug discovery:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
In Vivo:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
Biomarker Discovery:Article Title: The economic costs of precision medicine for clinical translational research among children with high-risk cancer
Article Snippet: Supplementary Table 1: Average labour hours Labour Mean Hours* (per patient) Multi-Omics Data Generation Sample preparation 4.60 WGS Bioinformatics 1.17 Ribonucleic acid sequencing Bioinformatics 0.85 Analysis and interpretation Curation 11.96 MTB preparation 13.83 MTB meeting 1.31 MTB reporting 6.97 Preclinical testing Sample processing Haematological 1 Brain Tumour 2.5 Extra Cranial Solid Tumour 4.5 In vitro HTS drug screening Haematological 16 Brain Tumour 7 Extra Cranial Solid Tumour 5 In vivo expansion Haematological 16.5 Brain Tumour (in vitro expansion) 20.0 Extra Cranial Solid Tumour 10.0 In vivo efficacy Haematological 100 Brain Tumour N/A Extra Cranial Solid Tumour 100 Model Validation Haematological 1 Brain Tumour 1 Extra Cranial Solid Tumour 1 Data Analysis HTS 17.73 In vivo efficacy 16.79 * Actual labour costs vary according to complexity of analysis, quality of samples, Suite of tests completed per patient.
|